Free Trial
→ Urgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20th (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$30.87
-0.2%		$29.45
$13.74
▼
$65.30
$7.20B2.4410.30 million shs15.98 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$38.62
0.0%		$43.42
$35.12
▼
$64.16
$172.53B0.7615.28 million shs9.61 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
0.00%+6.57%+12.47%-10.27%-42.82%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+3.52%-10.25%-21.62%-32.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$30.87
-0.2%		$29.45
$13.74
▼
$65.30
$7.20B2.4410.30 million shs15.98 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$38.62
0.0%		$43.42
$35.12
▼
$64.16
$172.53B0.7615.28 million shs9.61 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
0.00%+6.57%+12.47%-10.27%-42.82%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+3.52%-10.25%-21.62%-32.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.13
Hold$32.435.08% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.00
Hold$60.1455.71% Upside

Current Analyst Ratings Breakdown

Latest HIMS and NVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
10/8/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D+)
9/29/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/29/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell
9/22/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cfra logo
Cfra
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell$38.00
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
9/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$32.00
9/10/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$2.35B3.07$0.84 per share36.95$2.38 per share12.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B3.69$4.69 per share8.24$6.58 per share5.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$128.37M-$0.63N/A70.15N/A-5.51%-6.51%-1.20%11/9/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.099.4411.331.2735.36%58.61%20.91%11/4/2026 (Estimated)

Latest HIMS and NVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.0566N/AN/AN/A$892.88 millionN/A
11/4/2026Q3 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.7520N/AN/AN/A$11.13 billionN/A
8/10/2026Q2 2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$0.0498-$0.37-$0.3202-$0.37$698.90 million$753.21 million
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77$0.96+$0.19$0.72$10.89 billion$11.98 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.812.10%+21.74%19.80%N/A

Latest HIMS and NVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.57862.58%8/17/20268/17/20268/25/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
4.21
0.93
0.87
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.55
0.87
0.66

Institutional Ownership

CompanyInstitutional Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
11.76%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2,442233.31 million205.88 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Bristol Myers Squibb (NYSE: BMY) Or Novo Nordisk (NYSE: NVO): Which Healthcare Stock Offers The Better Investment Case In 2026?
October 10 at 12:06 AM  |  foreignpolicyjournal.comF
Novo Nordisk (NYSE: NVO) Stock Price Closes Higher As Broader Markets Fall
October 10 at 1:08 AM  |  foreignpolicyjournal.comF
Novo Nordisk (CPSE:NOVO B) Gets FDA Review Update As New EASD Data Land
October 9 at 10:06 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-081210591.html
Citi Cuts Novo Nordisk Price Target to DKK 296 on Limited Margin Growth Outlook
October 9 at 10:06 AM  |  investorshub.advfn.comhttps://investorshub.advfn.com/market-news/article/37777/citi-cuts-novo-nordisk-price-target-to-dkk-296-on-limited-margin-growth-outlook
Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth
October 9 at 10:06 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-nvo-raised-outlook-132822998.html
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
October 8, 2026  |  fool.comhttps://www.fool.com/investing/2026/10/08/ubs-called-novo-nordisk-a-value-trap-heres-the-oth/
Novo Nordisk’s CEO Was Asked Why His Stock Keeps Falling on Good News: ‘The Stock Market Is Always Right, but With a Bit of a Time Difference’
October 8, 2026  |  barchart.comhttps://www.barchart.com/story/news/5091202/novo-nordisks-ceo-was-asked-why-his-stock-keeps-falling-on-good-news-the-stock-market-is-always-right-but-with-a-bit-of-a-time-difference
Novo Nordisk Wraps Up Real World Joint Health Study for Esperoct in Haemophilia A
October 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/novo-nordisk-wraps-up-real-world-joint-health-study-for-esperoct-in-haemophilia-a?utm_source=marketbeat.com&utm_medium=referral
A declining-to-rising stock chart graphic, and text reading "Buy the Dip" and "Now".
Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI (NVO)
...
October 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/articles/only-20-stocks-are-holding-up-the-market-3-bargains-outside-ai/
Head-To-Head Contrast: Tarsus Pharmaceuticals (NASDAQ:TARS) versus Novo Nordisk A/S (NYSE:NVO)
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098950
Novo Nordisk stock loses 0.29 percent pre-market to EUR 33.91
October 8, 2026  |  ad-hoc-news.deA
Novo Nordisk's Liver-Fat Win Meets a Street Waiting for November Proof
October 7, 2026  |  ad-hoc-news.deA
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
October 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-nvo-increases-despite-204505225.html
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
October 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3002183/novo-nordisk-nvo-increases-despite-market-slip-here-s-what-you-need-to-know?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6-3002183
Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?
October 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-cpse-novo-b-130956416.html
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
October 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3001796/can-nvo-s-semaglutide-push-create-growth-beyond-cardiometabolic-care?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-3001796
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
October 6, 2026  |  fool.comhttps://www.fool.com/investing/2026/10/06/novo-stock-is-down-more-than-70-from-its-peak-valu/
Novo Nordisk's Oral Wegovy Data Land as CFRA Turns Bearish on the Stock
October 6, 2026  |  ad-hoc-news.deA
Novo Nordisk (NVO): Pipeline Timing Matters as GLP-1 Competition Intensifies
October 6, 2026  |  news.alphastreet.comN
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
October 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3000789/is-most-watched-stock-novo-nordisk-a-s-nvo-worth-betting-on-now?cid=cs-stocknewsapi-ft-fundamental_analysis|most_searched_stocks-3000789
FDA extends denecimig review: Novo Nordisk stock loses 1.02 percent
October 6, 2026  |  ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Shopping bags sit on a polished marble floor inside an upscale retail store or shopping mall.
3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
By Nathan Reiff | September 16, 2026
Laptop displaying the Hims & Hers logo beside a gavel, pill bottle, and declining stock chart with the US Capitol.
Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
By Jessica Mitacek | September 24, 2026
Novo Nordisk logo displayed in a laboratory setting with vials, an insulin pen, and a researcher in the background.
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
By Thomas Hughes | September 23, 2026
Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$30.87 -0.05 (-0.17%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$30.70 -0.17 (-0.54%)
As of 08:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$38.62 -0.02 (-0.04%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$38.77 +0.15 (+0.38%)
As of 08:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas